drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s patients. Axsome, meanwhile, recently reported positive results in its ...

Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...

Axsome (AXSM) said the results support the efficacy and safety of AXS-05 in the treatment of agitation in Alzheimer's patients. The company plans to submit a New Drug Application to the FDA for ...

People suffering from the early onset of Alzheimer's disease are being given access to a revolutionary drug that's being hailed ... but exercise has been proven as the best method of delaying ...

IGC Pharma, Inc, an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe, and ...

(NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in ...

(NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in ...

(NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in ...